149 related articles for article (PubMed ID: 16246947)
1. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients.
Marx N; Wöhrle J; Nusser T; Walcher D; Rinker A; Hombach V; Koenig W; Höher M
Circulation; 2005 Nov; 112(18):2792-8. PubMed ID: 16246947
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study.
Takagi T; Yamamuro A; Tamita K; Yamabe K; Katayama M; Mizoguchi S; Ibuki M; Tani T; Tanabe K; Nagai K; Shiratori K; Morioka S; Yoshikawa J
Am Heart J; 2003 Aug; 146(2):E5. PubMed ID: 12891212
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone could improve clinical outcomes after coronary stent implantation in nondiabetic patients with metabolic syndrome.
Cao Z; Zhou YJ; Zhao YX; Liu YY; Guo YH; Cheng WJ
Chin Med J (Engl); 2006 Jul; 119(14):1171-5. PubMed ID: 16863608
[TBL] [Abstract][Full Text] [Related]
4. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial.
Meisner F; Walcher D; Gizard F; Kapfer X; Huber R; Noak A; Sunder-Plassmann L; Bach H; Haug C; Bachem M; Stojakovic T; März W; Hombach V; Koenig W; Staels B; Marx N
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):845-50. PubMed ID: 16410460
[TBL] [Abstract][Full Text] [Related]
5. Randomized blinded clinical trial of intracoronary brachytherapy with 90Sr/Y beta-radiation for the prevention of restenosis after stent implantation in native coronary arteries in diabetic patients.
Syeda B; Schukro C; Kirisits C; Lang I; Siostrzonek P; Gottsauner-Wolf M; Pokrajac B; Schmid R; Yahya N; Pötter R; Glogar D
Radiother Oncol; 2006 Jan; 78(1):60-6. PubMed ID: 16309769
[TBL] [Abstract][Full Text] [Related]
6. Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome.
Katayama T; Ueba H; Tsuboi K; Kubo N; Yasu T; Kuroki M; Saito M; Momomura S; Kawakami M
Am Heart J; 2007 May; 153(5):762.e1-7. PubMed ID: 17452150
[TBL] [Abstract][Full Text] [Related]
7. Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: late "catch-up" phenomenon from ASPECT Study.
Park DW; Hong MK; Mintz GS; Lee CW; Song JM; Han KH; Kang DH; Cheong SS; Song JK; Kim JJ; Weissman NJ; Park SW; Park SJ
J Am Coll Cardiol; 2006 Dec; 48(12):2432-9. PubMed ID: 17174179
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease (SCANDSTENT) trial.
Kelbaek H; Helqvist S; Thuesen L; Kløvgaard L; Jørgensen E; Saunamäki K; Krusell LR; Bøtker HE; Engstrøm T; Jensen GV;
Am Heart J; 2006 Nov; 152(5):882-6. PubMed ID: 17070149
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation.
Radke PW; Figulla HR; Drexler H; Klues HG; Mügge A; Silber S; Daniel W; Schmeisser A; Reifart N; Motz W; Büttner HJ; Fischer D; Ortlepp JR; Schaefers K; Hoffmann R; Hanrath P;
Am Heart J; 2006 Oct; 152(4):761.e1-6. PubMed ID: 16996855
[TBL] [Abstract][Full Text] [Related]
10. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study.
Rodriguez AE; Granada JF; Rodriguez-Alemparte M; Vigo CF; Delgado J; Fernandez-Pereira C; Pocovi A; Rodriguez-Granillo AM; Schulz D; Raizner AE; Palacios I; O'Neill W; Kaluza GL; Stone G;
J Am Coll Cardiol; 2006 Apr; 47(8):1522-9. PubMed ID: 16630986
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib.
Zohlnhöfer D; Hausleiter J; Kastrati A; Mehilli J; Goos C; Schühlen H; Pache J; Pogatsa-Murray G; Heemann U; Dirschinger J; Schömig A
J Am Coll Cardiol; 2005 Dec; 46(11):1999-2003. PubMed ID: 16325031
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1.
Joner M; Farb A; Cheng Q; Finn AV; Acampado E; Burke AP; Skorija K; Creighton W; Kolodgie FD; Gold HK; Virmani R
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):182-9. PubMed ID: 17068283
[TBL] [Abstract][Full Text] [Related]
14. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial.
Peters S; Götting B; Trümmel M; Rust H; Brattström A
J Invasive Cardiol; 2001 Feb; 13(2):93-7. PubMed ID: 11176015
[TBL] [Abstract][Full Text] [Related]
15. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.
Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G
J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
[TBL] [Abstract][Full Text] [Related]
17. A single center investigation of bare-metal or drug-eluting stent restenosis from 1633 consecutive Chinese Han ethnic patients.
Xu B; Li JJ; Yang YJ; Ma WH; Chen JL; Qiao SB; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL
Chin Med J (Engl); 2006 Apr; 119(7):533-8. PubMed ID: 16620692
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice.
Dawkins KD; Grube E; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Koglin J; Russell ME;
Circulation; 2005 Nov; 112(21):3306-13. PubMed ID: 16286586
[TBL] [Abstract][Full Text] [Related]
19. Drug-eluting stent-supported percutaneous coronary intervention for chronic total coronary occlusion.
Migliorini A; Moschi G; Vergara R; Parodi G; Carrabba N; Antoniucci D
Catheter Cardiovasc Interv; 2006 Mar; 67(3):344-8. PubMed ID: 16489559
[TBL] [Abstract][Full Text] [Related]
20. A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird durable polymer rapamycin-eluting stent for the treatment of coronary artery disease in a "real world" setting: six-month follow-up results.
Liu HB; Xu B; Qiao SB; Yang YJ; Ma WH; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Li JJ; Chen JL; Gao RL
Chin Med J (Engl); 2007 Apr; 120(7):574-7. PubMed ID: 17442205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
